| $337M | ||
| $259M | ||
| $100M | ||
| $79M | ||
| $60M | ||
| $58M |
Buys | $0 | 0 | 0 |
Sells | $2,640 | 1 | 100 |
| BORGESON JOHN A. | See Remarks | 0 | $0 | 1 | $2,640 | $-2,640 |
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
Over the last 12 months, insiders at Kodiak Sciences Inc. have bought $0 and sold $2,640 worth of Kodiak Sciences Inc. stock.
On average, over the past 5 years, insiders at Kodiak Sciences Inc. have bought $166.29M and sold $6.45M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 13,155 shares for transaction amount of $104,363 was made by BAKER FELIX () on 2022‑06‑02.
| 2025-06-17 | Sale | BORGESON JOHN A. | See Remarks | 723 0.0014% | $3.65 | $2,640 | +5.92% | |
| 2024-06-17 | Sale | BORGESON JOHN A. | See Remarks | 2,874 0.0053% | $2.75 | $7,904 | +34.57% | |
| 2024-06-12 | Sale | BORGESON JOHN A. | See Remarks | 1,558 0.0031% | $2.92 | $4,549 | +28.67% | |
| 2023-06-16 | Sale | BORGESON JOHN A. | See Remarks | 2,749 0.0054% | $9.23 | $25,373 | -64.78% | |
| 2023-06-16 | Sale | EHRLICH JASON | See Remarks | 2,258 0.0044% | $9.23 | $20,841 | -64.78% | |
| 2023-06-14 | Sale | BORGESON JOHN A. | See Remarks | 1,448 0.0029% | $9.42 | $13,640 | -64.84% | |
| 2023-06-14 | Sale | EHRLICH JASON | See Remarks | 1,132 0.0023% | $9.42 | $10,663 | -64.84% | |
| 2022-06-15 | Sale | BORGESON JOHN A. | See Remarks | 2,798 0.0053% | $7.02 | $19,642 | +3.65% | |
| 2022-06-15 | Sale | EHRLICH JASON | See Remarks | 2,282 0.0043% | $7.02 | $16,020 | +3.65% | |
| 2022-06-02 | BAKER FELIX | 13,155 0.0255% | $7.93 | $104,363 | -6.75% | |||
| 2022-05-25 | BAKER FELIX | 116 0.0002% | $6.75 | $784 | +10.48% | |||
| 2022-05-16 | BAKER FELIX | 8,118 0.0163% | $5.99 | $48,599 | +29.47% | |||
| 2022-02-25 | Sale | PERLROTH VICTOR | Chairman and CEO | 340,000 0.6641% | $8.99 | $3.06M | -12.81% | |
| 2022-02-24 | Sale | PERLROTH VICTOR | Chairman and CEO | 1M 1.9233% | $9.20 | $9.2M | -16.03% | |
| 2022-02-17 | BAKER BROS. ADVISORS LP | 300,000 0.5801% | $54.56 | $16.37M | -28.56% | |||
| 2022-02-16 | BAKER BROS. ADVISORS LP | 95,165 0.1782% | $54.12 | $5.15M | -30.14% | |||
| 2022-02-15 | BAKER BROS. ADVISORS LP | 5,800 0.0107% | $54.16 | $314,099 | -31.11% | |||
| 2022-01-31 | BAKER BROS. ADVISORS LP | 30,148 0.0563% | $57.22 | $1.73M | -32.88% | |||
| 2022-01-28 | BAKER BROS. ADVISORS LP | 55,258 0.0977% | $50.42 | $2.79M | -27.90% | |||
| 2022-01-27 | BAKER BROS. ADVISORS LP | 262,259 0.5015% | $51.76 | $13.57M | -24.08% |
| BORGESON JOHN A. | See Remarks | 183316 0.3474% | $947,743.72 | 0 | 9 | |
| BAKER FELIX | 15617369 29.5988% | $80.74M | 3 | 0 | +11.07% | |
| BAKER BROS. ADVISORS LP | 14734965 27.9264% | $76.18M | 41 | 0 | +11.65% | |
| PERLROTH VICTOR | Chairman and CEO | 2168038 4.109% | $11.21M | 0 | 2 | |
| Liang Hong | SVP, Discovery Medicine | 130166 0.2467% | $672,958.22 | 0 | 3 | |
| EHRLICH JASON | See Remarks | 61924 0.1174% | $320,147.08 | 0 | 32 | |
| PROFUSEK ROBERT | director | 10000 0.019% | $51,700.00 | 1 | 0 | <0.0001% |
| Levy Richard S | director | 1000 0.0019% | $5,170.00 | 1 | 0 | +41% |
$5,911,307 | 70 | -1.38% | $272.55M | |
$54,762,250 | 63 | -1.52% | $244.34M | |
$87,639,490 | 62 | 18.37% | $300.08M | |
Kodiak Sciences Inc. (KOD) | $613,304,943 | 46 | 11.85% | $272.79M |
$17,983,739 | 41 | 102.87% | $274.75M | |
$2,545,071 | 34 | 16.59% | $254.33M | |
$74,231,875 | 30 | 40.62% | $258.08M | |
$3,668,031 | 23 | 2.05% | $302.85M | |
$12,110,219 | 14 | 336.38% | $267.42M | |
$59,012,381 | 12 | 28.63% | $286.35M | |
$57,263,116 | 11 | -8.37% | $282.16M | |
$6,847,110 | 9 | 5.96% | $238.58M | |
$14,995,689 | 8 | 3.76% | $292.9M | |
$5,905,507 | 7 | 2.69% | $248.08M | |
$8,286,963 | 6 | 3.09% | $242.77M | |
$58,352 | 4 | -43.78% | $279.45M | |
$73,632,168 | 3 | -63.24% | $298.65M | |
$879,499 | 1 | 28.50% | $245.95M | |
$63,731 | 1 | -19.50% | $290.18M |
| Increased Positions | 62 | +54.87% | 4M | +10.58% |
| Decreased Positions | 48 | -42.48% | 3M | -8.3% |
| New Positions | 21 | New | 866,803 | New |
| Sold Out Positions | 18 | Sold Out | 551,622 | Sold Out |
| Total Postitions | 127 | +12.39% | 43M | +2.28% |
| Baker Bros. Advisors Lp | $83,090.00 | 32.66% | 17.31M | 0 | 0% | 2024-12-31 |
| Blackrock, Inc. | $17,913.00 | 7.04% | 3.73M | +4,348 | +0.12% | 2025-03-31 |
| Vanguard Group Inc | $8,075.00 | 3.17% | 1.68M | -2,920 | -0.17% | 2024-12-31 |
| Acadian Asset Management Llc | $7,355.00 | 2.89% | 1.53M | -421,885 | -21.59% | 2024-12-31 |
| Price T Rowe Associates Inc /Md/ | $6,089.00 | 2.39% | 1.27M | +1M | +10,982.55% | 2024-12-31 |
| Tcg Crossover Management, Llc | $5,499.00 | 2.16% | 1.15M | +137,380 | +13.63% | 2024-12-31 |
| Adage Capital Partners Gp, L.L.C. | $5,470.00 | 2.15% | 1.14M | +1M | New | 2024-12-31 |
| Iconiq Capital, Llc | $4,881.00 | 1.92% | 1.02M | 0 | 0% | 2024-12-31 |
| Boxer Capital Management, Llc | $4,800.00 | 1.89% | 1M | +1M | New | 2024-12-31 |
| Silverarc Capital Management, Llc | $4,800.00 | 1.89% | 1M | +500,000 | New | 2024-12-31 |